Use of omalizumab in the treatment of food allergy and anaphylaxis

Jay Lieberman, Mirna Chehade

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Omalizumab is a humanized monoclonal anti-IgE antibody that is currently FDA-approved for allergic asthma. Given its mechanism of action, recent reports have suggested its possible clinical use for food allergy and some forms of anaphylaxis. Omalizumab exerts its action by binding to circulating IgE, reducing IgE receptor expression, and decreasing mediator release from mast cells and basophils. Clinical trials using omalizumab in patients with food allergy resulted in achieving tolerance to higher amounts of the allergen in some patients. When used as an adjunct therapy during immunotherapy trials in patients with food allergy and anaphylaxis, omalizumab allowed more rapid and higher doses of immunotherapy to be given. Omalizumab has also been reported to be effective in a few patients with idiopathic anaphylaxis and mast cell disorders. Large multi-center trials are needed to confirm the above findings, and to identify subsets of patients that would benefit the most from omalizumab.

Original languageEnglish (US)
Pages (from-to)78-84
Number of pages7
JournalCurrent Allergy and Asthma Reports
Volume13
Issue number1
DOIs
StatePublished - Feb 1 2013

Fingerprint

Food Hypersensitivity
Anaphylaxis
Mast Cells
Immunotherapy
Therapeutics
IgE Receptors
Basophils
Allergens
Immunoglobulin E
Omalizumab
Asthma
Monoclonal Antibodies
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

Use of omalizumab in the treatment of food allergy and anaphylaxis. / Lieberman, Jay; Chehade, Mirna.

In: Current Allergy and Asthma Reports, Vol. 13, No. 1, 01.02.2013, p. 78-84.

Research output: Contribution to journalArticle

@article{df54ef154548478b8ee29d8d835cfa02,
title = "Use of omalizumab in the treatment of food allergy and anaphylaxis",
abstract = "Omalizumab is a humanized monoclonal anti-IgE antibody that is currently FDA-approved for allergic asthma. Given its mechanism of action, recent reports have suggested its possible clinical use for food allergy and some forms of anaphylaxis. Omalizumab exerts its action by binding to circulating IgE, reducing IgE receptor expression, and decreasing mediator release from mast cells and basophils. Clinical trials using omalizumab in patients with food allergy resulted in achieving tolerance to higher amounts of the allergen in some patients. When used as an adjunct therapy during immunotherapy trials in patients with food allergy and anaphylaxis, omalizumab allowed more rapid and higher doses of immunotherapy to be given. Omalizumab has also been reported to be effective in a few patients with idiopathic anaphylaxis and mast cell disorders. Large multi-center trials are needed to confirm the above findings, and to identify subsets of patients that would benefit the most from omalizumab.",
author = "Jay Lieberman and Mirna Chehade",
year = "2013",
month = "2",
day = "1",
doi = "10.1007/s11882-012-0316-x",
language = "English (US)",
volume = "13",
pages = "78--84",
journal = "Current Allergy and Asthma Reports",
issn = "1529-7322",
publisher = "Current Medicine Group",
number = "1",

}

TY - JOUR

T1 - Use of omalizumab in the treatment of food allergy and anaphylaxis

AU - Lieberman, Jay

AU - Chehade, Mirna

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Omalizumab is a humanized monoclonal anti-IgE antibody that is currently FDA-approved for allergic asthma. Given its mechanism of action, recent reports have suggested its possible clinical use for food allergy and some forms of anaphylaxis. Omalizumab exerts its action by binding to circulating IgE, reducing IgE receptor expression, and decreasing mediator release from mast cells and basophils. Clinical trials using omalizumab in patients with food allergy resulted in achieving tolerance to higher amounts of the allergen in some patients. When used as an adjunct therapy during immunotherapy trials in patients with food allergy and anaphylaxis, omalizumab allowed more rapid and higher doses of immunotherapy to be given. Omalizumab has also been reported to be effective in a few patients with idiopathic anaphylaxis and mast cell disorders. Large multi-center trials are needed to confirm the above findings, and to identify subsets of patients that would benefit the most from omalizumab.

AB - Omalizumab is a humanized monoclonal anti-IgE antibody that is currently FDA-approved for allergic asthma. Given its mechanism of action, recent reports have suggested its possible clinical use for food allergy and some forms of anaphylaxis. Omalizumab exerts its action by binding to circulating IgE, reducing IgE receptor expression, and decreasing mediator release from mast cells and basophils. Clinical trials using omalizumab in patients with food allergy resulted in achieving tolerance to higher amounts of the allergen in some patients. When used as an adjunct therapy during immunotherapy trials in patients with food allergy and anaphylaxis, omalizumab allowed more rapid and higher doses of immunotherapy to be given. Omalizumab has also been reported to be effective in a few patients with idiopathic anaphylaxis and mast cell disorders. Large multi-center trials are needed to confirm the above findings, and to identify subsets of patients that would benefit the most from omalizumab.

UR - http://www.scopus.com/inward/record.url?scp=84872608684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872608684&partnerID=8YFLogxK

U2 - 10.1007/s11882-012-0316-x

DO - 10.1007/s11882-012-0316-x

M3 - Article

C2 - 23065311

AN - SCOPUS:84872608684

VL - 13

SP - 78

EP - 84

JO - Current Allergy and Asthma Reports

JF - Current Allergy and Asthma Reports

SN - 1529-7322

IS - 1

ER -